David R. Spigel

Overview

Best Publications

• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  14371
  Citations

• Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

  H. Borghaei;L. Paz-Ares;L. Horn;D. R. Spigel

  9411
  Citations

• Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

  Julie Brahmer;Karen L Reckamp;Paul Baas;Lucio Crinò

  8692
  Citations

• Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

  Scott J. Antonia;Augusto Villegas;Davey Daniel;David Vicente

  2538
  Citations

• Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

  Luis Paz-Ares;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  1754
  Citations

• STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

  Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  1559
  Citations

• Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

  Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  1342
  Citations

• A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

  J. Randolph Hecht;Edith Mitchell;Tarek Chidiac;Carroll Scroggin

  1205
  Citations

• Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

  Roy S Herbst;Giuseppe Giaccone;Filippo de Marinis;Niels Reinmuth

  1203
  Citations

• First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

  Lecia V. Sequist;Renato G. Martins;David Spigel;Steven M. Grunberg

  1029
  Citations

• Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

  M C Liu;G R Oxnard;E A Klein;C Swanton

  1017
  Citations

• Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

  Leora Horn;David R. Spigel;Everett E. Vokes;Esther Holgado

  946
  Citations

• Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

  Scott Gettinger;Leora Horn;David Jackman;David Spigel

  681
  Citations

• Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

  Alice T Shaw;Tae Min Kim;Lucio Crinò;Cesare Gridelli

  591
  Citations

• First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

  Neal Ready;Matthew D. Hellmann;Mark M. Awad;Gregory A. Otterson

  526
  Citations

• Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

  David R. Spigel;Thomas J. Ervin;Rodryg A. Ramlau;Davey B. Daniel

  524
  Citations

• Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

  Charles M Rudin;M Catherine Pietanza;Todd M Bauer;Neal Ready

  517
  Citations

• Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

  Martin Reck;Alexander Luft;Aleksandra Szczesna;Libor Havel

  513
  Citations

• Five-Year Survival and Correlates among Patients with Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated with Nivolumab

  Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  505
  Citations

• Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

  Jonathan W Goldman;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  498
  Citations